Transcriptome-wide Mendelian randomization during CD4⁺ T cell activation reveals immune-related drug targets for cardiometabolic diseases.

ABSTRACT: Immunity has shown potentials in informing drug development for cardiometabolic diseases, such as type 2 diabetes (T2D) and coronary artery disease (CAD). Here, we performed a transcriptome-wide Mendelian randomization (MR) study to estimate the putative causal effects of 11,021 gene expression profiles during CD4⁺ T cells activation on the development of T2D and CAD. Robust MR and colocalization evidence was observed for 162 genes altering T2D risk and 80 genes altering CAD risk, with 12% and 16% respectively demonstrating CD4⁺ T cell specificity. We observed temporal causal patterns during T cell activation in 69 gene-T2D pairs and 34 gene-CAD pairs. These genes were eight times more likely to show robust genetic evidence. We further identified 25 genes that were ta

SUBMITTER: Wu X 

PROVIDER: S-EPMC11519452 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature